Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin

Isabelle Gouin-Thibault; Michel M. Samama

doi:10.1160/TH08-10-0705

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(05): 986-987
DOI: 10.1160/TH08-10-0705

Letters to the Editor

Schattauer GmbH

Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin

Isabelle Gouin-Thibault

¹Assistance Publique Hôpitaux de Paris, Charles Foix, Laboratoire d’Hématologie, Ivry sur Seine, France

²Université Paris Descartes, INSERM U765, Paris, France

,

Michel M. Samama

³Assistance Publique Hôpitaux de Paris, Service d’Hématologie Biologique, Hôpital Hôtel Dieu, Paris, France

› Author Affiliations

Abstract

Full Text

References

References
1 Hérault JP, Bernat A, Roye F. et al. Pharmacokinetics of new synthetic heparin mimetics. Thomb Haemost 2002; 87: 985-989.
2 Harenberg J, Jörg I, Vukojevic Y. et al. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observation from the van Gogh trials. Eur J Clin Pharmacol 2008; 64: 555-563.
3 Veyrat-Follet C, Vivier N, Trellu M. et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost. 2009 in press.
4 Gouin-Thibault I, Dingler E, Maris A. et al. In vitro interaction of the pentasaccharide idraparinux (SanOrg 34006) with unfractinated heparin. J Thromb Haemost 2003; 09: 2054-2056.
5 Olson ST, Swanson R, Raub-Segall E. et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Thromb Heamost 2004; 92: 929-939.
6 Hoppensteadt D, Walenga J, Jeske W. et al. Lack of dose-response with Fondaparinux and Idraparinux is due to endogenous antithrombin saturation. J Thromb Haemost 2003; 07 (Suppl. 02) P2069 (Abstract).
7 van Gogh Investigators. Buller HR, Cohen AT. et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
8 van Gogh Investigators. Buller HR, Cohen AT. et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.
9 Buller HR, Destors JM, Gallus AS. et al. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (Equinox study): safety, efficacy and reversibility by avidin. Blood. 2008 112: Abstract 12.